{
    "nct_id": "NCT05538130",
    "official_title": "A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",
    "inclusion_criteria": "* Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation\n* Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation\n* For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma\n* For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,\n* For Substudy B and C, measurable disease by RECIST version 1.1\n* For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II/III alteration in tumor tissue and/or blood\n* For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II/III BRAF alteration)\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Brain metastasis larger than 4 cm\n* History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)",
    "miscellaneous_criteria": ""
}